Krystal Biotech (KRYS) EBITDA Margin (2017 - 2026)
Krystal Biotech (KRYS) posted EBITDA Margin of 57.05% for Q3 2026, up 13.31 percentage points from 43.74% a year earlier and up 6.87 percentage points from the prior quarter.
Powered by 
Analysis
Krystal Biotech (KRYS) EBITDA Margin (2017 - 2026) Analysis & Trends
For the trailing twelve months through Sep 30, 2026, EBITDA Margin at Krystal Biotech was 49.67%, up 5.74 percentage points year-over-year; for FY2025, it was 42.92%, up 18.22 percentage points from FY2024.
- In prior years, Krystal Biotech's EBITDA Margin was 24.70% in FY2024 (+233.55 pp) and -208.85% in FY2023.
- The Q3 2026 figure stands as the highest quarterly EBITDA Margin in data going back to Q3 2023.
- On a year-over-year basis, EBITDA Margin has increased in each of the last three quarters, with an average year-over-year change of +19.33 percentage points over the last eight quarters.
- The strongest year-over-year quarter for EBITDA Margin in the past five years was Q3 2024, with a gain of 322.50 percentage points; the weakest was Q4 2025, with a drop of 4.19 percentage points.
- According to Business Quant data, EBITDA Margin for the three prior quarters was 50.17% (Q2 2026), 47.43% (Q1 2026) and 42.76% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Krystal Biotech | 9.08 Bn | 5.67 Bn | 119.79 Mn | 57.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 57.05% |
| Jun 30, 2026 | 50.17% |
| Mar 31, 2026 | 47.43% |
| Dec 31, 2025 | 42.76% |
| Sep 30, 2025 | 43.74% |
| Jun 30, 2025 | 42.38% |
| Mar 31, 2025 | 42.70% |
| Dec 31, 2024 | 46.94% |
| Sep 30, 2024 | 28.35% |
| Jun 30, 2024 | 14.75% |
| Mar 31, 2024 | -11.60% |
| Dec 31, 2023 | 11.28% |
| Sep 30, 2023 | -294.14% |
| Jun 30, 2022 | -4,306.51% |
| Mar 31, 2022 | -19,146.69% |
| Dec 31, 2021 | -30,131.43% |
| Sep 30, 2021 | -23,601.59% |
| Jun 30, 2021 | -52,423.33% |
| Mar 31, 2021 | -41,869.70% |
| Dec 31, 2020 | -26,837.84% |
API Access
Krystal Biotech EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KRYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "KRYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KRYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();